Loading…

Donor Graft Cytomegalovirus Serostatus and the Risk of Arterial and Venous Thrombotic Events in Seronegative Recipients After Non-Thoracic Solid Organ Transplantation

Abstract Background Cytomegalovirus (CMV) is the most common opportunistic pathogen, following solid organ transplantation (SOT), that leads to direct and indirect effects. The aim of this study was to assess the impact of CMV exposure at transplantation on the rate of posttransplant thrombotic even...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases 2021-03, Vol.72 (5), p.845-852
Main Authors: Belga, Sara, MacDonald, Clayton, Chiang, Diana, Kabbani, Dima, Shojai, Soroush, Abraldes, Juan G, Cervera, Carlos
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c320t-8db397e3f94d76d84b2a2930ddbda4dd30e588cd0f5c91f676125ed117d37cd13
cites cdi_FETCH-LOGICAL-c320t-8db397e3f94d76d84b2a2930ddbda4dd30e588cd0f5c91f676125ed117d37cd13
container_end_page 852
container_issue 5
container_start_page 845
container_title Clinical infectious diseases
container_volume 72
creator Belga, Sara
MacDonald, Clayton
Chiang, Diana
Kabbani, Dima
Shojai, Soroush
Abraldes, Juan G
Cervera, Carlos
description Abstract Background Cytomegalovirus (CMV) is the most common opportunistic pathogen, following solid organ transplantation (SOT), that leads to direct and indirect effects. The aim of this study was to assess the impact of CMV exposure at transplantation on the rate of posttransplant thrombotic events (TEs). Methods We conducted a retrospective cohort study of patients transplanted at the University of Alberta Hospital between July 2005 and January 2018. We included adult SOT CMV-seronegative recipients at transplantation who received an allograft from either a seropositive donor (D+/R-) or a seronegative donor (D-/R-). Results A total of 392 SOT recipients were included: 151 (39%) liver, 188 (48%) kidney, 45 (11%) pancreas, and 8 (2%) other transplants. The mean age was 47 years, 297 (76%) were males, and 181 (46%) had a CMV D+/R- donor. Patients in the CMV D+/R- cohort were slightly older (51 years versus 48 years in the D-/R- cohort; P = .036), while other variables, including cardiovascular risk factors and pretransplant TEs, were not different between groups. Overall, TEs occurred in 35 (19%) patients in the CMV D+/R- group, versus 21 (10%) in the CMV D-/R- group, at 5 years of follow-up (P = .008); the incidence rates per 100 transplant months were 5.12 and 1.02 in the CMV D+/R- and CMV D-/R- groups, respectively (P = .003). After adjusting for potential confounders with a Cox regression model, a CMV D+/R- transplantation was independently associated with an increased risk of a TE over 5 years (adjusted hazard ratio, 3.027; 95% confidence interval, 1.669–5.488). Conclusions A CMV D+/R- transplantation is associated with an increased risk of a TE posttransplantation. In this retrospective cohort study of cytomegalovirus (CMV)-naive solid organ transplant recipients, the CMV donor-positive serostatus at transplantation was the strongest independent predictor of thrombotic events posttransplant, when adjusted for the most relevant confounders.
doi_str_mv 10.1093/cid/ciaa125
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2352053758</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/cid/ciaa125</oup_id><sourcerecordid>2352053758</sourcerecordid><originalsourceid>FETCH-LOGICAL-c320t-8db397e3f94d76d84b2a2930ddbda4dd30e588cd0f5c91f676125ed117d37cd13</originalsourceid><addsrcrecordid>eNp9kUFPGzEQhS0EaijtiTvyCSGhBXu9znqPUQhpJQRSSXtdeW1vYti1F9uJlD_E7-w0STlysDzSfPPseQ-hc0puKKnYrbIajpQ050folHJWZmNe0WOoCRdZIZgYoa8xvhBCqSD8CxqxnOS8JMUper_zzgc8D7JNeLpNvjdL2fmNDeuIn03wMckEpXQap5XBv2x8xb7Fk5BMsLLbNf4Y54FZrILvG5-swrONcSli63YaDjST3cC0UXawu9akBQH86F22WPkgFQw9-85q_BSW0uFFkC4OnXTwvPXuGzppZRfN98N9hn7fzxbTH9nD0_zndPKQKVgpZUI3rCoNa6tCl2MtiiaXecWI1o2WhdaMGC6E0qTlqqLtuByDaUZTWmpWKk3ZGbra6w7Bv61NTHVvozIdfMTAinXOeE7AYS4Avd6jCkyKwbT1EGwvw7ampP4XTA3B1IdggL44CK-b3ugP9n8SAFzuAb8ePlX6C1IFmuY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2352053758</pqid></control><display><type>article</type><title>Donor Graft Cytomegalovirus Serostatus and the Risk of Arterial and Venous Thrombotic Events in Seronegative Recipients After Non-Thoracic Solid Organ Transplantation</title><source>Oxford Journals Online</source><creator>Belga, Sara ; MacDonald, Clayton ; Chiang, Diana ; Kabbani, Dima ; Shojai, Soroush ; Abraldes, Juan G ; Cervera, Carlos</creator><creatorcontrib>Belga, Sara ; MacDonald, Clayton ; Chiang, Diana ; Kabbani, Dima ; Shojai, Soroush ; Abraldes, Juan G ; Cervera, Carlos</creatorcontrib><description>Abstract Background Cytomegalovirus (CMV) is the most common opportunistic pathogen, following solid organ transplantation (SOT), that leads to direct and indirect effects. The aim of this study was to assess the impact of CMV exposure at transplantation on the rate of posttransplant thrombotic events (TEs). Methods We conducted a retrospective cohort study of patients transplanted at the University of Alberta Hospital between July 2005 and January 2018. We included adult SOT CMV-seronegative recipients at transplantation who received an allograft from either a seropositive donor (D+/R-) or a seronegative donor (D-/R-). Results A total of 392 SOT recipients were included: 151 (39%) liver, 188 (48%) kidney, 45 (11%) pancreas, and 8 (2%) other transplants. The mean age was 47 years, 297 (76%) were males, and 181 (46%) had a CMV D+/R- donor. Patients in the CMV D+/R- cohort were slightly older (51 years versus 48 years in the D-/R- cohort; P = .036), while other variables, including cardiovascular risk factors and pretransplant TEs, were not different between groups. Overall, TEs occurred in 35 (19%) patients in the CMV D+/R- group, versus 21 (10%) in the CMV D-/R- group, at 5 years of follow-up (P = .008); the incidence rates per 100 transplant months were 5.12 and 1.02 in the CMV D+/R- and CMV D-/R- groups, respectively (P = .003). After adjusting for potential confounders with a Cox regression model, a CMV D+/R- transplantation was independently associated with an increased risk of a TE over 5 years (adjusted hazard ratio, 3.027; 95% confidence interval, 1.669–5.488). Conclusions A CMV D+/R- transplantation is associated with an increased risk of a TE posttransplantation. In this retrospective cohort study of cytomegalovirus (CMV)-naive solid organ transplant recipients, the CMV donor-positive serostatus at transplantation was the strongest independent predictor of thrombotic events posttransplant, when adjusted for the most relevant confounders.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1093/cid/ciaa125</identifier><identifier>PMID: 32025704</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Adult ; Antiviral Agents - therapeutic use ; Cytomegalovirus ; Cytomegalovirus Infections - drug therapy ; Cytomegalovirus Infections - epidemiology ; Female ; Humans ; Male ; Middle Aged ; Organ Transplantation - adverse effects ; Retrospective Studies</subject><ispartof>Clinical infectious diseases, 2021-03, Vol.72 (5), p.845-852</ispartof><rights>The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. 2020</rights><rights>The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c320t-8db397e3f94d76d84b2a2930ddbda4dd30e588cd0f5c91f676125ed117d37cd13</citedby><cites>FETCH-LOGICAL-c320t-8db397e3f94d76d84b2a2930ddbda4dd30e588cd0f5c91f676125ed117d37cd13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32025704$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Belga, Sara</creatorcontrib><creatorcontrib>MacDonald, Clayton</creatorcontrib><creatorcontrib>Chiang, Diana</creatorcontrib><creatorcontrib>Kabbani, Dima</creatorcontrib><creatorcontrib>Shojai, Soroush</creatorcontrib><creatorcontrib>Abraldes, Juan G</creatorcontrib><creatorcontrib>Cervera, Carlos</creatorcontrib><title>Donor Graft Cytomegalovirus Serostatus and the Risk of Arterial and Venous Thrombotic Events in Seronegative Recipients After Non-Thoracic Solid Organ Transplantation</title><title>Clinical infectious diseases</title><addtitle>Clin Infect Dis</addtitle><description>Abstract Background Cytomegalovirus (CMV) is the most common opportunistic pathogen, following solid organ transplantation (SOT), that leads to direct and indirect effects. The aim of this study was to assess the impact of CMV exposure at transplantation on the rate of posttransplant thrombotic events (TEs). Methods We conducted a retrospective cohort study of patients transplanted at the University of Alberta Hospital between July 2005 and January 2018. We included adult SOT CMV-seronegative recipients at transplantation who received an allograft from either a seropositive donor (D+/R-) or a seronegative donor (D-/R-). Results A total of 392 SOT recipients were included: 151 (39%) liver, 188 (48%) kidney, 45 (11%) pancreas, and 8 (2%) other transplants. The mean age was 47 years, 297 (76%) were males, and 181 (46%) had a CMV D+/R- donor. Patients in the CMV D+/R- cohort were slightly older (51 years versus 48 years in the D-/R- cohort; P = .036), while other variables, including cardiovascular risk factors and pretransplant TEs, were not different between groups. Overall, TEs occurred in 35 (19%) patients in the CMV D+/R- group, versus 21 (10%) in the CMV D-/R- group, at 5 years of follow-up (P = .008); the incidence rates per 100 transplant months were 5.12 and 1.02 in the CMV D+/R- and CMV D-/R- groups, respectively (P = .003). After adjusting for potential confounders with a Cox regression model, a CMV D+/R- transplantation was independently associated with an increased risk of a TE over 5 years (adjusted hazard ratio, 3.027; 95% confidence interval, 1.669–5.488). Conclusions A CMV D+/R- transplantation is associated with an increased risk of a TE posttransplantation. In this retrospective cohort study of cytomegalovirus (CMV)-naive solid organ transplant recipients, the CMV donor-positive serostatus at transplantation was the strongest independent predictor of thrombotic events posttransplant, when adjusted for the most relevant confounders.</description><subject>Adult</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Cytomegalovirus</subject><subject>Cytomegalovirus Infections - drug therapy</subject><subject>Cytomegalovirus Infections - epidemiology</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Organ Transplantation - adverse effects</subject><subject>Retrospective Studies</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kUFPGzEQhS0EaijtiTvyCSGhBXu9znqPUQhpJQRSSXtdeW1vYti1F9uJlD_E7-w0STlysDzSfPPseQ-hc0puKKnYrbIajpQ050folHJWZmNe0WOoCRdZIZgYoa8xvhBCqSD8CxqxnOS8JMUper_zzgc8D7JNeLpNvjdL2fmNDeuIn03wMckEpXQap5XBv2x8xb7Fk5BMsLLbNf4Y54FZrILvG5-swrONcSli63YaDjST3cC0UXawu9akBQH86F22WPkgFQw9-85q_BSW0uFFkC4OnXTwvPXuGzppZRfN98N9hn7fzxbTH9nD0_zndPKQKVgpZUI3rCoNa6tCl2MtiiaXecWI1o2WhdaMGC6E0qTlqqLtuByDaUZTWmpWKk3ZGbra6w7Bv61NTHVvozIdfMTAinXOeE7AYS4Avd6jCkyKwbT1EGwvw7ampP4XTA3B1IdggL44CK-b3ugP9n8SAFzuAb8ePlX6C1IFmuY</recordid><startdate>20210301</startdate><enddate>20210301</enddate><creator>Belga, Sara</creator><creator>MacDonald, Clayton</creator><creator>Chiang, Diana</creator><creator>Kabbani, Dima</creator><creator>Shojai, Soroush</creator><creator>Abraldes, Juan G</creator><creator>Cervera, Carlos</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20210301</creationdate><title>Donor Graft Cytomegalovirus Serostatus and the Risk of Arterial and Venous Thrombotic Events in Seronegative Recipients After Non-Thoracic Solid Organ Transplantation</title><author>Belga, Sara ; MacDonald, Clayton ; Chiang, Diana ; Kabbani, Dima ; Shojai, Soroush ; Abraldes, Juan G ; Cervera, Carlos</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c320t-8db397e3f94d76d84b2a2930ddbda4dd30e588cd0f5c91f676125ed117d37cd13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adult</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Cytomegalovirus</topic><topic>Cytomegalovirus Infections - drug therapy</topic><topic>Cytomegalovirus Infections - epidemiology</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Organ Transplantation - adverse effects</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Belga, Sara</creatorcontrib><creatorcontrib>MacDonald, Clayton</creatorcontrib><creatorcontrib>Chiang, Diana</creatorcontrib><creatorcontrib>Kabbani, Dima</creatorcontrib><creatorcontrib>Shojai, Soroush</creatorcontrib><creatorcontrib>Abraldes, Juan G</creatorcontrib><creatorcontrib>Cervera, Carlos</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Belga, Sara</au><au>MacDonald, Clayton</au><au>Chiang, Diana</au><au>Kabbani, Dima</au><au>Shojai, Soroush</au><au>Abraldes, Juan G</au><au>Cervera, Carlos</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Donor Graft Cytomegalovirus Serostatus and the Risk of Arterial and Venous Thrombotic Events in Seronegative Recipients After Non-Thoracic Solid Organ Transplantation</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clin Infect Dis</addtitle><date>2021-03-01</date><risdate>2021</risdate><volume>72</volume><issue>5</issue><spage>845</spage><epage>852</epage><pages>845-852</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><abstract>Abstract Background Cytomegalovirus (CMV) is the most common opportunistic pathogen, following solid organ transplantation (SOT), that leads to direct and indirect effects. The aim of this study was to assess the impact of CMV exposure at transplantation on the rate of posttransplant thrombotic events (TEs). Methods We conducted a retrospective cohort study of patients transplanted at the University of Alberta Hospital between July 2005 and January 2018. We included adult SOT CMV-seronegative recipients at transplantation who received an allograft from either a seropositive donor (D+/R-) or a seronegative donor (D-/R-). Results A total of 392 SOT recipients were included: 151 (39%) liver, 188 (48%) kidney, 45 (11%) pancreas, and 8 (2%) other transplants. The mean age was 47 years, 297 (76%) were males, and 181 (46%) had a CMV D+/R- donor. Patients in the CMV D+/R- cohort were slightly older (51 years versus 48 years in the D-/R- cohort; P = .036), while other variables, including cardiovascular risk factors and pretransplant TEs, were not different between groups. Overall, TEs occurred in 35 (19%) patients in the CMV D+/R- group, versus 21 (10%) in the CMV D-/R- group, at 5 years of follow-up (P = .008); the incidence rates per 100 transplant months were 5.12 and 1.02 in the CMV D+/R- and CMV D-/R- groups, respectively (P = .003). After adjusting for potential confounders with a Cox regression model, a CMV D+/R- transplantation was independently associated with an increased risk of a TE over 5 years (adjusted hazard ratio, 3.027; 95% confidence interval, 1.669–5.488). Conclusions A CMV D+/R- transplantation is associated with an increased risk of a TE posttransplantation. In this retrospective cohort study of cytomegalovirus (CMV)-naive solid organ transplant recipients, the CMV donor-positive serostatus at transplantation was the strongest independent predictor of thrombotic events posttransplant, when adjusted for the most relevant confounders.</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>32025704</pmid><doi>10.1093/cid/ciaa125</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1058-4838
ispartof Clinical infectious diseases, 2021-03, Vol.72 (5), p.845-852
issn 1058-4838
1537-6591
language eng
recordid cdi_proquest_miscellaneous_2352053758
source Oxford Journals Online
subjects Adult
Antiviral Agents - therapeutic use
Cytomegalovirus
Cytomegalovirus Infections - drug therapy
Cytomegalovirus Infections - epidemiology
Female
Humans
Male
Middle Aged
Organ Transplantation - adverse effects
Retrospective Studies
title Donor Graft Cytomegalovirus Serostatus and the Risk of Arterial and Venous Thrombotic Events in Seronegative Recipients After Non-Thoracic Solid Organ Transplantation
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T01%3A04%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Donor%20Graft%20Cytomegalovirus%20Serostatus%20and%20the%20Risk%20of%20Arterial%20and%20Venous%20Thrombotic%20Events%20in%20Seronegative%20Recipients%20After%20Non-Thoracic%20Solid%20Organ%20Transplantation&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Belga,%20Sara&rft.date=2021-03-01&rft.volume=72&rft.issue=5&rft.spage=845&rft.epage=852&rft.pages=845-852&rft.issn=1058-4838&rft.eissn=1537-6591&rft_id=info:doi/10.1093/cid/ciaa125&rft_dat=%3Cproquest_cross%3E2352053758%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c320t-8db397e3f94d76d84b2a2930ddbda4dd30e588cd0f5c91f676125ed117d37cd13%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2352053758&rft_id=info:pmid/32025704&rft_oup_id=10.1093/cid/ciaa125&rfr_iscdi=true